Treatment Summary and Care Plan for Breast Cancer Survivors: acceptability and feasibility study

Maria das Graças Silva Matsubara1, Fabiana Baroni Alves Makdissi1, Simone Elias2

  • 1AC Camargo Cancer Center, São Paulo, SP, Brazil.

to evaluate the acceptability and feasibility of the Treatment Summary and Care Plan for Breast Cancer Survivors (TSSCP-P Br) document.

this was a cross-sectional, quantitative and qualitative study involving women who had completed treatment for breast cancer (n=50) and nurses (n=10) who incorporated the document into the care plan at outpatient follow-up appointments during the experimental phase of a clinical study. The feasibility and acceptability questionnaires were administered in the last data collection stage of the experiment. The data was analyzed using descriptive statistics and content analysis.

in the evaluation of the surviving women, feasibility showed retention of 98.0% and adherence of 99.3%. Acceptability in terms of suitability, convenience, efficacy and adherence reached 81.6%. From the professionals' perspective, feasibility and acceptability were 84.2%, in terms of suitability, convenience, effectiveness, risks, availability, training, fidelity, reach and resources. The document was praised and the main problems in practice were pointed out, such as professional experience.

the Treatment Summary and Care Plan proved to be feasible and acceptable for the clinical practice of caring for women who have survived breast cancer.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Nursing Evaluation01:15

Nursing Evaluation

The evaluation stage signals the end of the nursing process. The nurse gathers evaluative data to assess whether or not the patient has attained the expected results. Whereas the nurse collects data in the nursing assessment to identify the patient's health concerns, the evaluation stage data determines if the indicated health issues are resolved. Evaluative data collection includes two sections: the data acquired to evaluate patient outcomes and the time criteria for data collection.
3.6K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
289
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
270